Kymera's New Drug Shows Promise in Eczema & Asthma Trial
Update: 2025-12-08
Description
Kymera Therapeutics shares soared by over forty percent following positive early trial results for its new oral anti-inflammatory drug, KT-six-two-one. The drug showed significant inflammation reduction in eczema and asthma patients by targeting the STAT-six protein. Kymeras CEO, Nello Mainolfi, expressed excitement, highlighting the trials success and the companys progress in degrading the STAT-six protein. Phase Two B trials for eczema and asthma patients are underway, with results expected in 2027 and early 2023, respectively, potentially offering improved treatment options for millions of people with chronic inflammatory conditions.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
